IP Library Patent Application 15684125
Patent Application
App. No. 15/684,125

CANCER PEPTIDE VACCINE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/684,125
Abstract

A composition for treating cancer, comprising 6 to 13 peptides derived from tumor antigens, wherein the composition is used in the manner that antibodies to the respective peptides in the peripheral blood of a patient are measured and peptides to which antibodies are positive are selected and administered to the patient, and a peptide selection method.

Claims (15)

1 - 15 . (canceled)

16 . A kit comprising a group of twelve peptides consisting of SEQ ID NOs:1 and 4-14.

17 . The kit of claim 16 , wherein each peptide is contained in an individual vial.

18 . The kit of claim 16 , wherein 2 or more of the twelve peptides are contained in a vial.

19 . The kit of claim 16 , wherein each of the twelve peptides is a powder.

20 . The kit of claim 16 , wherein each of the twelve peptides is in solution.

21 . The kit of claim 20 , wherein each solution further comprises a solvent.

22 . The kit of claim 21 , wherein the solvent is selected from the group consisting of saline, an alkali metal hydrocarbon aqueous solution, and a mixture thereof.

23 . The kit of claim 22 , wherein the alkali metal hydrocarbon is selected from the group consisting of lithium hydrogencarbonate, sodium hydrogencarbonate, and potassium hydrogencarbonate.

24 . The kit of claim 21 , wherein the alkali metal hydrocarbon aqueous solution contains 1% to 6% w/v % of the alkali metal hydrocarbon.

25 . The kit of claim 20 , wherein the concentration of each peptide in solution is 0.1% to 0.4% by mass.

26 . The kit of claim 20 , wherein each peptide solution further comprises an adjuvant.

27 . The kit of claim 26 , wherein the adjuvant is selected from the group consisting of Freund's incomplete adjuvant, polysaccharides, Freund's complete adjuvant, BCG, alum, GM-CSF, IL-2, and CpG.

28 . The kit of claim 16 , further comprising another antitumor agent in addition to the twelve peptides.

29 . The kit of claim 28 , wherein another antitumor agent is selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, topoisomerase inhibitors, microtubule polymerization inhibitors, hormones, and molecular-targeted agents.

Assignments (2)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Oct 16, 2017
From: BRIGHTPATH BIOTHERAPEUTICS CO., LTD.
To: BRIGHTPATH BIOTHERAPEUTICS CO., LTD.
Reel/Frame 044212/0009 →
CHANGE OF NAME Recorded Sep 11, 2017
From: GREEN PEPTIDE CO., LTD.
To: BRIGHTPATH BIOTHERAPEUTICS CO., LTD.
Reel/Frame 043811/0854 →